Asthma
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability of the dry powder formulation of ASM-024 following single and multiple administration by inhalation of ascending doses in healthy subjects and subjects with stable moderate asthma.
Detailed description
This is a phase I/II, randomized, double-blind, placebo-controlled study of single ascending and multiple ascending doses of ASM-024 administered by dry powder inhalation to healthy subjects and subjects with stable moderate asthma. The goal of this study is to evaluate the safety, tolerability and pharmacokinetic profile of a new, dry powder formulation of ASM-024. The doses that will be tested in subjects with asthma will be determined based on the information collected first in healthy volunteers. In addition to standard safety and tolerability evaluations, the acute effects of the study medication on the airways will be assessed.
Interventions
DRUGASM-024
Ascending doses of ASM-024
Sponsors
Asmacure Ltée
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy Volunteers: * Healthy male or female adult, 18 to 55 years of age ; non-smoker or former smoker; * Normal lung function; and * Normal 12-lead ECG Asthmatics: * Male or female adult, 18 to 60 years of age with diagnosis of moderate asthma according to the GINA Guidelines and on regular inhaled corticosteroids with or without short or long-acting beta 2-agonists; * Non-smoker or former smoker; * FEV1 ≥ 70 % predicted in the absence of medications for asthma; * Baseline methacholine PC20 ≤ 16 mg/mL; and * Normal 12-lead ECG.
Exclusion criteria
Healthy Volunteers: * Clinically significant illness or surgery within 8 weeks prior to first administration of the study medication; * Significant medical history that, in the Investigator's opinion, may adversely affect participation; * History of allergy or significant adverse reaction to drugs similar to ASM-024, to nicotine, or to cholinergic drugs or any drugs with a similar chemical structure; * History of hypersensitivity (anaphylaxis, angioedema) to any drug; * Use of any drug known to induce or inhibit hepatic drug metabolism, within 30 days prior to first administration of the study medication; * Positive pregnancy test for female subjects; * Use of medications known to prolong QT/QTc interval within 14 days prior to the first administration of the study medication; * Clinically significant 12 lead ECG abnormalities at Screening;; * Clinically significant physical examination or laboratory findings at Screening; * History of alcohol or drug abuse; * Tobacco use within 12 months prior to Screening, or nicotine-containing products within 6 months prior to Screening. History of smoking must be ≤ 10 pack-years; * Positive hepatitis B or C or HIV test at Screening; * Investigational drug within 30 days prior to first administration of the study medication, or long-acting investigational drug within 90 days prior to first administration of the study medication; * Previous exposure to ASM-024; and * Women of child-bearing potential and male participants unwilling or unable to use accepted methods of birth control. Asthmatics: * Clinically significant illness or surgery within 8 weeks prior to first administration of the study medication; * Significant medical history that, in the Investigator's opinion, may adversely affect participation; * History of allergy or significant adverse reaction to drugs similar to ASM-024, to nicotine, or to cholinergic drugs or any drugs with a similar chemical structure; * History of hypersensitivity (anaphylaxis, angioedema) to any drug; * Use of any drug known to induce or inhibit hepatic drug metabolism, within 30 days prior to first administration of the study medication; * Positive pregnancy test for female subjects; * Use of medications known to prolong QT/QTc interval; * Clinically significant 12 lead ECG at Screening; * Clinically significant physical examination or laboratory findings or abnormal vital signs; * Baseline methacholine PC20 \> 16 mg/mL at Screening; * History of illicit drug use or alcohol abuse within 12 months of Screening; * Tobacco use within 12 months prior to Screening, or nicotine-containing products within 6 months prior to Screening. History of smoking must be ≤ 10 pack-years; * Positive hepatitis B or C or HIV test at Screening; * Any of the following concomitant medications preceding the administration of methacholine during Screening and preceding the administration of the study medication at Visit 1: (i) oral or i.v. corticosteroids within 1 month; (ii) inhaled or intranasal corticosteroids within 48 hours; (iii) long-acting beta-2-agonists within 48 hours; (iv) short-acting beta-2-agonists within 8 hours; (v) anticholinergic aerosol within 24 hours; (vi) theophyline-containing products within 48 hours; (vii) NSAIDs within 7 days preceding the administration of methacholine during Screening and throughout the study; and (viii) antihistaminic drugs within 3 days; * Investigational drug within 30 days of Screening; long-acting investigational drug within 90 days of Screening; * Previous exposure to ASM-024; and * Women of child-bearing potential and male participants unwilling or unable to use accepted methods of birth control.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adverse events, spirometry | up to 7 days |
Countries
Canada
Outcome results
None listed